#United States #Teaneck #Clinical Trials #Cognizant #Medidata

Cognizant Deepens Collaboration with Medidata

Cognizant Technology Solutions (Nasdaq: CTSH) has announced a significant expansion of its partnership with Medidata, a leader in clinical trial solutions owned by Dassault Systèmes. This enhanced collaboration aims to provide specialized support for clients in the life sciences sector, ultimately helping to improve clinical trial efficiency and patient outcomes.

A Commitment to Life Sciences Innovation

The renewed partnership reflects both companies' commitment to transforming the landscape of clinical research through cutting-edge technology and expertise. By integrating Medidata's advanced AI-driven technologies with Cognizant's operational excellence and industry know-how, the organizations are poised to streamline research and development efforts, enabling clients to derive actionable insights from complex data.

As part of this multi-year agreement, Cognizant is dedicating a specialized team of Medidata Platform experts to assist pharmaceutical companies, biotech firms, medical device manufacturers, contract research organizations, and patients who utilize Medidata’s services. The goal is to maximize the functional value of Medidata for its extensive client base.

Joanne Smith, Vice President of Client Services at Cognizant, stated, “Our partnership with Medidata allows us to work hand-in-hand with life sciences organizations to leverage the full potential of their clinical operations. We are dedicated to improving user satisfaction so that our clients can concentrate on what truly matters: developing innovative therapies that transform patient care.”

Enhancing Client Experience Through Technology

The collaboration focuses on enhancing the user experience for Medidata’s clients by providing tailored solutions backed by a robust support system. This includes comprehensive services such as user acceptance testing, systems integration, and the establishment of a patient service desk. The companies are determined to offer life sciences organizations the tools they need to adapt and thrive in a rapidly changing environment.

Medidata’s EVP, Janet Butler, highlighted the benefits of this partnership: “By combining our technology platform with Cognizant’s industry insights and efficient operations, we empower our life sciences clients to modernize their processes. This ultimately leads to more informed decision-making and improved patient outcomes.”

AI-Powered Technologies at the Forefront

Cognizant and Medidata's collaboration is set to leverage AI technologies significantly. Tools such as the Medidata Clinical Data Studio and Medidata Health Record Connect will provide life sciences clients with enhanced capability to analyze data and help expedite the clinical development processes. These platforms, combined with the patient portal myMedidata, deliver tailored experiences for patients, study sites, and data management — streamlining research and development workflows in the life sciences sector.

As Cognizant continues to position itself as a top Global Medidata Strategic Alliance Partner, its certified professionals play a crucial role in modernizing clinical operations and data management for organizations focused on advancing healthcare.

A Future Focused on Patient Outcomes

Mohammad Haque, Senior Vice President at Cognizant, expressed excitement about the partnership's direction, stating, “We are thrilled to accelerate our collaboration with Medidata. Our joint efforts will allow clients to utilize next-generation AI capabilities effectively, significantly impacting patient outcomes.”

The partnership between Cognizant and Medidata represents a promising evolution in the life sciences field, enabling clients to maximize the potential of their clinical data while facilitating innovations that improve patient care and outcomes.

For more information on Cognizant's services and partnership efforts, visit Cognizant's website.